Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Express News | Quince Therapeutics: Expects Potential Nda Submission to FDA & Marketing Authorization Application Submission to EMA in 2026
Express News | Quince Therapeutics: Expects to Report Topline Results in Q4 of 2025
Express News | Quince Therapeutics Announces the Lancet Neurology Publication of Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (a-T)
Express News | Quince Therapeutics- Qtrly Reported a Net Loss of $27.7 Mln, or a Net Loss of $0.64 per Basic and Diluted Share
Express News | Quince Therapeutics - Strong Cash Position Expected to Provide Sufficient Operating Runway Into 2026
Quince Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Quince Therapeutics Doses First Subject in Ataxia-Telangiectasia Trial
Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Express News | Quince Expects Phase 3 Neat Results H2 2025
Express News | Quince Therapeutics Initiates Phase 3 Trial of Erydex
Express News | Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia
FDA Fast Tracks Quince Therapeutics' Rare Ataxia Drug EryDex
FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia
Express News | Quince Therapeutics Receives U.S. FDA Fast Track Designation for Erydex System
Quince Therapeutics | 10-Q: Q1 2024 Earnings Report
Quince Therapeutics 1Q Research and Development Expenses of $3.7M >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX